Evaluation of anti-TGF-β2 antibody as a new postoperative anti-scarring agent in glaucoma surgery

Investigative Ophthalmology and Visual Science

Volumn 44, Issue 8, 2003, Pages 3394-3401

  Mead, Anna L ^a,c   Wong, Tina T L ^a   Cordeiro, M Francesca ^a   Anderson, Ian K ^b   Khaw, Peng T ^a  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

^b MEDIMMUNE LTD   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LERDELIMUMAB; MONOCLONAL ANTIBODY; TRANSFORMING GROWTH FACTOR BETA2 ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORNEA EPITHELIUM; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; EXTRACELLULAR MATRIX; GLAUCOMA; GLAUCOMA SURGERY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MORPHOLOGY; NONHUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RABBIT; SCAR FORMATION; TREATMENT OUTCOME; WOUND HEALING;

ANIMALS; ANTIBODIES, MONOCLONAL; CICATRIX; CONJUNCTIVAL DISEASES; FIBROSIS; FILTERING SURGERY; GLAUCOMA; INJECTIONS; POSTOPERATIVE COMPLICATIONS; RABBITS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA2; WOUND HEALING;

EID: 0041342109     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.02-0978     Document Type: Article

References (46)

1. Addicks EM, Quigley HA, Green WR, Robin AL. Histologic characteristics of filtering blebs in glaucomatous eyes. Arch Ophthalmol. 1983;101:795-798.
2. Hitchings RA, Grierson I. Clinico pathological correlation in eyes with failed fistulizing surgery. Trans Ophthalmol Soc UK. 1983; 103:84-88.
3. Jay JL. Rational choice of therapy in primary open angle glaucoma. Eye. 1992;6:243-247.
4. Migdal C, Gregory W, Hitchings R. Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology. 1994;101:1651-1656.
5. The Fluorouracil Filtering Surgery Study Group. Fluorouracil Filtering Surgery Study one-year follow-up. Am J Ophthalmol. 1989; 108:625-635.
6. The Fluorouracil Filtering Surgery Study Group. Five-year follow-up of the Fluorouracil Filtering Surgery Study. Am J Ophthalmol. 1996;121:349-366.
7. Goldenfeld M, Krupin T, Ruderman JM, et al. 5-Fluorouracil in initial trabeculectomy: a prospective, randomized, multicenter study. Ophthalmology. 1994;101:1024-1029.
8. Heuer DK, Parrish RK, Gressel MG, et al. 5-Fluorouracil and glaucoma filtering surgery. III. Intermediate follow-up of a pilot study. Ophthalmology. 1986;93:1537-1546.
9. Rothman RF, Liebmann JM, Ritch R. Low-dose 5-fluorouracil trabeculectomy as initial surgery in uncomplicated glaucoma: long-term follow up. Ophthalmology. 2000;107:1184-1190.
10. Lamping KA, Belkin JK. 5-Fluorouracil and mitomycin C in pseudophakic patients. Ophthalmology. 1995;102:70-75.
11. Katz GJ, Higginbotham EJ, Lichter PR, et al. Mitomycin C versus 5-fluorouracil in high-risk glaucoma filtering surgery: extended follow-up. Ophthalmology. 1995;102:1263-1269.
12. Khaw PT, Doyle JW, Sherwood MB, Smith MF, McGorray S. Effects of intraoperative 5-fluorouracil or mitomycin C on glaucoma filtration surgery in the rabbit. Ophthalmology. 1993;100:367-372.
13. Allen LE, Manuchehri K, Corridan PG. The treatment of encapsulated trabeculectomy blebs in an out-patient setting using a needling technique and subconjunctival 5-fluorouracil injection. Eye. 1998;12:119-123.
14. Mastropasqua L, Carpineto P, Ciancaglini M, Zuppardi E, Lobefalo L, Gallenga PE. Delayed post-operative use of 5-fluorouracil as an adjunct in medically uncontrolled open angle glaucoma. Eye. 1998;12:701-706
15. Shin DH, Juzych MS, Khatana AK, Swendris RP, Parrow KA. Needling revision of failed filtering blebs with adjunctive 5-fluorouracil. Ophthalmic Surg. 1993;24:242-248.
16. Ophir A, Ticho U. A randomized study of trabeculectomy and subconjunctival administration of fluorouracil in primary glaucomas. Arch Ophthalmol. 1992;110:1072-1075.
17. Ophir A, Porges Y. Needling with intra-bleb 5 fluorouracil for intractable neovascular glaucoma. Ophthalmic Surg Lasers. 2000; 31:38-42.
18. Gallenga PE, Mastropasqua L, Carpineto P, Ciancaglini M, Zuppardi E. Delayed post-operative use of 5-fluorouracil in primary open angle glaucoma. Acta Ophthalmol Scand Suppl. 1997;224:45-46.
19. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS) 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429-440.
20. Khaw PT, Doyle JW, Sherwood MB, Grierson I, Schultz G, McGorray S. Prolonged localized tissue effects from 5-minute exposures to fluorouracil and mitomycin C. Arch Ophthalmol. 1993;111:263-267.
21. Crowston JG, Akbar AN, Constable PH, Occleston NL, Daniels JT, Khaw PT. Antimetabolite-induced apoptosis in Tenon's capsule fibroblasts. Invest Ophthalmol Vis Sci. 1998;39:449-454.
22. Stamper RL, McMenemy MG, Lieberman MF. Hypotonous maculopathy after trabeculectomy with subconjunctival 5-fluorouracil. Am J Ophthalmol. 1992;114:544-553.
23. Parrish R, Minckler D. "Late endophthalmitis": filtering surgery time bomb? Ophthalmology. 1996;103:1167-1168.
24. Jampel HD, Pasquale LR, Dibernardo C. Hypotony maculopathy following trabeculectomy with mitomycin C. Arch Ophthalmol. 1992;110:1049-1050.
25. Cordeiro MF, Reichel MB, Gay JA, D'Esposita F, Alexander RA, Khaw PT. Transforming growth factor-beta1, -beta2, and -beta3 in vivo: effects on normal and mitomycin C-modulated conjunctival scarring. Invest Ophthalmol Vis Sci. 1999;40:1975-1982.
26. Cordeiro MF, Gay JA, Khaw PT. Human anti-transforming growth factor-beta2 antibody: a new glaucoma anti-scarring agent. Invest Ophthalmol Vis Sci. 1999;40:2225-2234.
27. Connor TB, Roberts AB, Sporn MB, et al. Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye. J Clin Invest. 1989;83:1661-1666.
28. Hales AM, Chamberlain CG, McAvoy JW. Cataract induction in lenses cultured with transforming growth factor-β. Invest Ophthalmol Vis Sci. 1995;36:1709-1713.
29. Khaw PT, Occleston NL, Schultz G, Grierson I, Sherwood MB, Larkin G. Activation and suppression of fibroblast function. Eye. 1994;8:188-195.
30. Lutty GA, Merges C, Threlkeld AB, Crone S, McLeod DS. Heterogeneity in localization of isoforms of TGF-beta in human retina, vitreous, and choroid. Invest Ophthalmol Vis Sci. 1993;34:477-487.
31. Pasquale LR, Dorman Pease ME, Lutty GA, Quigley HA, Jampel HD. Immunolocalization of TGF-beta 1, TGF-beta 2, and TGF-beta 3 in the anterior segment of the human eye. Invest Ophthalmol Vis Sci. 1993;34:23-30.
32. Tripathi RC, Chan WF, Li J, Tripathi BJ. Trabecular cells express the TGF-beta 2 gene and secrete the cytokine. Exp Eye Res. 1994;58:523-528.
33. Tripathi RC, Li J, Chan WF, Tripathi BJ. Aqueous humor in glaucomatous eyes contains an increased level of TGF-beta 2. Exp Eye Res. 1994;59:723-727.
34. Jampel HD, Roche N, Stark WJ, Roberts AB. Transforming growth factor-beta in human aqueous humor. Curr Eye Res. 1990;9:963-969.
35. Siriwardena D, Khaw PT, Kinng AJ, et al. Human anti-transforming growth factor b2 monoclonal antibody-A new modulator of wound healing in trabeculectomy: a randomised placebo controlled clinical study. Ophthalmology. 2002;109:427-431.
36. Shah M, Foreman DM, Ferguson MWJ. Neutralising antibody to TGF-b1, 2 reduces cutaneous scarring in adult rodents. J Cell Sci. 1994;107:1137-1157.
37. Chen CW. Enhanced intraocular pressure lowering effectiveness of trabeculectomy by local application of mitomycin C. Trans Asia Pacif Acad Ophthalmol 1983;9:172-177.
38. Doyle JW, Sherwood MB, Khaw PT, McGrory S, Smith MF. Intraoperative 5-fluorouracil for filtration surgery in the rabbit. Invest Ophthalmol Vis Sci. 1993;34:3313-3319.
39. Knisely TL, Bleicher PA, Vibbard CA, Granstein RD. Production of latent transforming growth factor-beta and other inhibitory factors by cultured murine iris and ciliary body cells. Curr Eye Res. 1991;10:761-771.
40. Schultz-Cherry S, Chen H, Mosher DF. Regulation of transforming growth factor beta activation by discrete sequences of thrombospondin. J Biol Chem. 1995;270:932-937.
41. Grainger DJ, Wakefield L, Bethell HW, Farndale RW, Metcalf JC. Release and activation of platelet latent TGF-beta in blood clots during dissolution with plasmin. Nat Med. 1995;1:932-937.
42. Kelley J, Shull S, Walsh JJ, Cutroneo KR, Absher M. Auto-induction of transforming growth factor-beta in human lung fibroblasts. Am J Respir Cell Mol Biol. 1993;8:417-424.
43. Li DQ, Lee SB, Tseng S. Differential expression and regulation of TGF-beta1, TGF-beta2, TGF-beta3, TGF-betaRI, TGF-betaRII and TGF-betaRIII in cultured human corneal, limbal, and conjunctival fibroblasts. Curr Eye Res. 1999;19:154-161.
44. Darby I, Skalli O, Gabbiani GA. Alpha-smooth muscle actin is transiently expressed by myofibroblasts during experimental wound healing. Lab Invest. 1990;63:21-29.
45. Desmouliere A, Geinoz A, Gabbiani F, Gabbiani G. Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol. 1993;122:103-111.
46. Ronnov-Jessen L, Petersen OW. Induction of alpha-smooth muscle actin by transforming growth factor-beta 1 in quiescent human breast gland fibroblasts. Implications for myofibroblast generation in breast neoplasia. Lab Invest. 1993;68:696-707.